Overall, our findings dissected a specific PBRM1-RAD51 dual-loss ccRCC subtype hyper-sensitive to immunotherapy and revealed its specific immuno-genomic profiles, which may shed light on precise ccRCC treatment decisions. This evidence concerns the gene RAD51 and nonpapillary renal cell carcinoma.